| Mar to Jun 2028Quarter disclosed | iza-bren (BMS-986507) | BMY | Topline readout | Breast Neoplasms | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | pumitamig (BNT327) | BMY | Topline readout | Early-Stage Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | iza-bren (BMS-986507) | BMY | Primary completion | Breast Neoplasms | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | pumitamig (BNT327) | BMY | Primary completion | Early-Stage Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | luspatercept (ACE-536) | BMY | Primary completion | Myelodysplastic Syndromes | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2028Quarter disclosed | golcadomide (BMS-986369) | BMY | Topline readout | Follicular Lymphoma | Scheduled | ClinicalTrials.gov |
| April 2028Month disclosed | golcadomide (BMS-986369) | BMY | Primary completion | Follicular Lymphoma | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | luspatercept (ACE-536) | BMY | Topline readout | — | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | zola-cel (CC-97540) | BMY | Topline readout | Lupus Erythematosus, Systemic; Lupus Nephritis | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | luspatercept (ACE-536) | BMY | Primary completion | — | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | zola-cel (CC-97540) | BMY | Primary completion | Lupus Erythematosus, Systemic; Lupus Nephritis | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Bipolar Disorder Type I With Mania | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Bipolar Disorder Type I With Mania | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | oral azacitidine (BMS-986345) | BMY | Topline readout | Myelodysplastic Syndromes | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | oral azacitidine (BMS-986345) | BMY | Primary completion | Myelodysplastic Syndromes | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2028Quarter disclosed | navlimetostat (BMS-986504) | BMY | Topline readout | Solid Tumors | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | navlimetostat (BMS-986504) | BMY | Primary completion | Solid Tumors | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Schizophrenia | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | pumitamig (BNT327) | BMY | Topline readout | — | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | pumitamig (BNT327) | BMY | Primary completion | — | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Schizophrenia | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | Krazati (adagrasib) | BMY | Topline readout | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | Krazati (adagrasib) | BMY | Primary completion | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Topline readout | Alzheimer Disease | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | BMS-986353 | BMY | Topline readout | Systemic Sclerosis | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | evifacotrep (BMS-986511) | BMY | Topline readout | Major Depressive Disorder | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | evifacotrep (BMS-986511) | BMY | Primary completion | Major Depressive Disorder | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | BMS-986353 | BMY | Primary completion | Systemic Sclerosis | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Primary completion | Alzheimer Disease | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | navlimetostat (BMS-986504) | BMY | Topline readout | Carcinoma, Non-Small-Cell Lung | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | iza-bren (BMS-986507) | BMY | Topline readout | Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | iza-bren (BMS-986507) | BMY | Primary completion | Non-Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | navlimetostat (BMS-986504) | BMY | Primary completion | Carcinoma, Non-Small-Cell Lung | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | Sotyktu (deucravacitinib) | BMY | Primary completion | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | Sotyktu (deucravacitinib) | BMY | Topline readout | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | iza-bren (BMS-986507) | BMY | Topline readout | Urothelial Cancer | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | iza-bren (BMS-986507) | BMY | Primary completion | Urothelial Cancer | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | Zenbexus (iberdomide hydrochloride) | BMY | Topline readout | Multiple Myeloma | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Topline readout | Schizophrenia | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Primary completion | Schizophrenia | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | Zenbexus (iberdomide hydrochloride) | BMY | Primary completion | Multiple Myeloma | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | navlimetostat (BMS-986504) | BMY | Topline readout | Pancreatic Ductal Adenocarcinoma | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | navlimetostat (BMS-986504) | BMY | Primary completion | Pancreatic Ductal Adenocarcinoma | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2029Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Alzheimer Disease; Agitation | Scheduled | ClinicalTrials.gov |
| June 2029Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Alzheimer Disease; Agitation | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | Opdivo® (nivolumab) | BMY | Topline readout | Cancer | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Irritability Associated With Autism Spectrum Disorder | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Irritability Associated With Autism Spectrum Disorder | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Irritability Associated With Autism Spectrum Disorder | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Irritability Associated With Autism Spectrum Disorder | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | Opdivo® (nivolumab) | BMY | Primary completion | Cancer | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2029Quarter disclosed | Krazati (adagrasib) | BMY | Topline readout | Carcinoma, Non-Small-Cell Lung | Scheduled | ClinicalTrials.gov |
| September 2029Month disclosed | Krazati (adagrasib) | BMY | Primary completion | Carcinoma, Non-Small-Cell Lung | Scheduled | ClinicalTrials.gov |
| Oct 2029 to Jan 2030Quarter disclosed | Sotyktu (deucravacitinib) | BMY | Topline readout | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| October 2029Month disclosed | Sotyktu (deucravacitinib) | BMY | Primary completion | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| Nov 2029 to Feb 2030Quarter disclosed | admilparant (BMS-986278) | BMY | Topline readout | Pulmonary Fibrosis | Scheduled | ClinicalTrials.gov |
| November 2029Month disclosed | admilparant (BMS-986278) | BMY | Primary completion | Pulmonary Fibrosis | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Schizophrenia | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Schizophrenia | Scheduled | ClinicalTrials.gov |
| Feb to May 2030Quarter disclosed | pumitamig (BNT327) | BMY | Topline readout | Untreated, Unresectable, or Metastatic Colorectal Cancer | Scheduled | ClinicalTrials.gov |
| February 2030Month disclosed | pumitamig (BNT327) | BMY | Primary completion | Untreated, Unresectable, or Metastatic Colorectal Cancer | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | Sotyktu (deucravacitinib) | BMY | Topline readout | Juvenile Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Schizophrenia; Autism-Related Irritability | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | Sotyktu (deucravacitinib) | BMY | Primary completion | Juvenile Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Schizophrenia; Autism-Related Irritability | Scheduled | ClinicalTrials.gov |
| May to Aug 2030Quarter disclosed | zolacabtagene autoleucel (BMS-986353) | BMY | Topline readout | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | Scheduled | ClinicalTrials.gov |
| May 2030Month disclosed | zolacabtagene autoleucel (BMS-986353) | BMY | Primary completion | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2030Quarter disclosed | Opdivo® (nivolumab) | BMY | Topline readout | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| July 2030Month disclosed | Opdivo® (nivolumab) | BMY | Primary completion | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2030Quarter disclosed | pumitamig (BNT327) | BMY | Topline readout | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| September 2030Month disclosed | pumitamig (BNT327) | BMY | Primary completion | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| Oct 2030 to Jan 2031Quarter disclosed | Sotyktu (deucravacitinib) | BMY | Topline readout | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis | Scheduled | ClinicalTrials.gov |
| October 2030Month disclosed | Sotyktu (deucravacitinib) | BMY | Primary completion | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis | Scheduled | ClinicalTrials.gov |
| Nov 2030 to Feb 2031Quarter disclosed | Opdivo® (nivolumab) | BMY | Topline readout | — | Scheduled | ClinicalTrials.gov |
| November 2030Month disclosed | Opdivo® (nivolumab) | BMY | Primary completion | — | Scheduled | ClinicalTrials.gov |